Shelter Pharma revenue jumps 44% as exports surge 164%
FY26 revenue hit Rs 73.13 crore on strong export and domestic expansion; EBITDA margin fell to 17% as spending on sales team and distribution weighed.
What's new
- FY26 revenue Rs 73.13 crore, up 44% YoY; Q4 revenue Rs 39.84 crore, up 50%.
- Exports Rs 6 crore in FY26 (164% YoY); Q1 FY27 already Rs 5+ crore.
- Domestic footprint expanded from 12 to 15+ states; sales team grew from 5 to 80.
- EBITDA margin compressed to 17% from 20-21% due to deliberate expansion spending.
Themes from the call
Demand
Revenue surged 44% on strong domestic and export demand; export growth 164% with Q1 FY27 already at Rs 5+ crore suggests acceleration.
Margins
EBITDA margin fell to 17% from historical 20-21% as spending on sales team and distribution weighed; management targets recovery to 20-22% near-term and 22-25% in 2-3 years as fixed costs spread over higher sales.
Capital allocation
New facility near Ahmedabad with Rs 12-15 crore capex from internal accruals; working capital cycle at 234 days, with credit terms being tightened from 120 to 60 days.
Guidance watch
- Revenue target Rs 200 crore by 2030 based on export momentum and pan-India expansion.
- EBITDA margin recovery to 20-22% near-term, 22-25% in 2-3 years as scale improves margins.
- Capex of Rs 12-15 crore for new facility, funded via internal accruals, completion end-2027.
- Pan-India domestic presence targeted by FY27.
Risk flags
- EBITDA margin compression to 17% needs to reverse as per guidance; any delay could signal overinvestment.
- Working capital cycle of 234 days is high; credit tightening to 60 days will test distributor appetite.
- Execution on new facility and domestic expansion aggressive; sales team doubling may stretch margins further near-term.
Key quotes
-
"This year in 2026, we did around 6.5 crores of business. Currently, in the first quarter of 2027, we have already exceeded 5 crores in exports."
— Mustakeem Sabugar, Management
The brief
Shelter Pharma delivered a 44% revenue surge in FY26 to Rs 73.13 crore, driven by a 164% jump in exports to Rs 6 crore and a domestic footprint expansion from 12 to 15 states. The export momentum is accelerating — Q1 FY27 has already clocked Rs 5 crore. But the growth came at a cost. EBITDA margin dropped from the historical 20-21% band to 17%, entirely from deliberate spending on a sales team scaled from 5 to 80 people and new distribution channels. Management sees this as an investment, not a permanent compression. It targets a recovery to 20-22% near-term and 22-25% in 2-3 years as volume growth absorbs fixed costs. A new manufacturing facility near Ahmedabad with Rs 12-15 crore capex (funded internally) is on track for end-2027, giving capacity for a Rs 200 crore revenue goal by 2030. The working capital cycle of 234 days — partly from liberal credit terms — is being tightened from 120 to 60 days as the company gains negotiating power. The story is one of deliberate scaling: revenue is rocketing, but margin recovery and working capital discipline will determine whether this is a high-quality growth story or a stretched one.
Shelter Pharma's revenue rocket is real, but margin recovery and working capital discipline are the next tests.